Evolution of ImmuPharma18 Apr 2022 15:58
https://www.investegate.co.uk/immupharma-plc--imm-/rns/corporate-update/202111180700027362S/
18 Nov 2021....RNS
Gives a detailed overview of product pipeline.
Commenting on the new corporate focus, Tim McCarthy, Chief Executive Officer said: "The evolvement and transition of ImmuPharma over the last few months can probably be summed up as one of the most challenging and yet exciting periods in its history. An enormous amount of collaborative teamwork has been involved to achieve the vastly improved position we have presented today.
As a Board, supported by our excellent pre-clinical team in Bordeaux and our collaboration partners, we are all unified in our belief that ImmuPharma is now positioned to be able to deliver on the key objectives and timetable outlined in this announcement and we are excited by this new phase in the evolution of ImmuPharma.
As CEO, I am committed to delivering key value inflexion points, as we progress through major milestones over the next 12 months."
Dr Tim Franklin, Chief Operating Officer of ImmuPharma, added : "As a newly formed Board, our first priority is to create long term value for our shareholders and to enhance and protect the key assets within our portfolio.
I am delighted with the positive progress, as outlined today with the PK study and look forward to continuing to work closely with Avion, as Lupuzor™ moves through its Phase 3 trial and towards the market.
We are also extremely pleased to be finalising a new expanded collaboration agreement with Professor Muller and her team at the CNRS to support the P140 franchise, and the development of the new proprietary synthesis of the P140 molecule, is a significant step in this direction.
Professor Sylviane Muller, Director at CNRS further said: "Myself and the team at the CNRS have been working, over many years, on a number of projects associated with the P140 mechanism of action and as such, are convinced of the enormous potential of the P140 platform and its diverse role within the whole spectrum of autoimmunity and inflammation.
I am particularly excited to see Lupuzor™ moving forward towards its next Phase 3 trial, as this drug will be literally life changing for many Lupus patients worldwide.
I also strongly believe that the new propriety synthesis for P140 being developed by ImmuPharma is absolutely the correct strategy, as it creates a more protected and valuable asset. Working in collaboration with ImmuPharma and its excellent pre-clinical team in Bordeaux, we are confident that we will be able to develop a number of new and innovative therapeutic opportunities moving forward."
Sign In
Follow the stocks
